MX382095B - Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos. - Google Patents
Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos.Info
- Publication number
- MX382095B MX382095B MX2018013349A MX2018013349A MX382095B MX 382095 B MX382095 B MX 382095B MX 2018013349 A MX2018013349 A MX 2018013349A MX 2018013349 A MX2018013349 A MX 2018013349A MX 382095 B MX382095 B MX 382095B
- Authority
- MX
- Mexico
- Prior art keywords
- benzoimidazol
- diethylamino
- acrylamide
- hydroxy
- butyl
- Prior art date
Links
- 150000001875 compounds Chemical group 0.000 abstract 2
- JHDKZFFAIZKUCU-UHFFFAOYSA-N 3-[2-butyl-1-[2-(diethylamino)ethyl]benzimidazol-5-yl]-n-hydroxyprop-2-enamide Chemical compound ONC(=O)C=CC1=CC=C2N(CCN(CC)CC)C(CCCC)=NC2=C1 JHDKZFFAIZKUCU-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662330673P | 2016-05-02 | 2016-05-02 | |
| PCT/US2017/030414 WO2017192451A1 (en) | 2016-05-02 | 2017-05-01 | Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018013349A MX2018013349A (es) | 2019-02-20 |
| MX382095B true MX382095B (es) | 2025-03-13 |
Family
ID=60203321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013349A MX382095B (es) | 2016-05-02 | 2017-05-01 | Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10626092B2 (OSRAM) |
| EP (2) | EP3939966A1 (OSRAM) |
| JP (1) | JP2019514905A (OSRAM) |
| KR (1) | KR20190005904A (OSRAM) |
| CN (1) | CN109414425A (OSRAM) |
| AR (1) | AR108257A1 (OSRAM) |
| AU (1) | AU2017261218A1 (OSRAM) |
| BR (1) | BR112018072439A2 (OSRAM) |
| CA (1) | CA3022011A1 (OSRAM) |
| CL (1) | CL2018003109A1 (OSRAM) |
| CO (1) | CO2018012941A2 (OSRAM) |
| EA (1) | EA201892341A1 (OSRAM) |
| ES (1) | ES2886495T3 (OSRAM) |
| IL (1) | IL262578A (OSRAM) |
| MA (1) | MA44880A (OSRAM) |
| MX (1) | MX382095B (OSRAM) |
| PH (1) | PH12018502296B1 (OSRAM) |
| SG (1) | SG11201809471UA (OSRAM) |
| TW (1) | TW201741286A (OSRAM) |
| WO (1) | WO2017192451A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018157742A1 (zh) * | 2017-02-28 | 2018-09-07 | 苏州科睿思制药有限公司 | Sb-939的盐的晶型及其制备方法和用途 |
| EP3728205A1 (en) | 2017-12-19 | 2020-10-28 | Assia Chemical Industries Ltd | Crystalline polymorphs of pracinostat and pracinostat salts |
| WO2019149262A1 (zh) * | 2018-02-05 | 2019-08-08 | 苏州科睿思制药有限公司 | Sb-939的晶型及其制备方法和用途 |
| US20230159468A1 (en) | 2020-04-22 | 2023-05-25 | Macfarlan Smith Limited | Novel forms of pracinostat dihydrochloride |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2291749A1 (fr) | 1974-11-20 | 1976-06-18 | Delalande Sa | Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique |
| ATE198601T1 (de) | 1992-05-20 | 2001-01-15 | Merck & Co Inc | Ester derivate von 4-aza-steroiden |
| SE9804212D0 (sv) | 1998-12-04 | 1998-12-04 | Astra Pharma Prod | Compounds |
| YU49401A (sh) | 1999-01-13 | 2004-07-15 | Warner-Lambert Company | Benzoheterocikli i njihova upotreba kao inhibitori mek |
| ATE253915T1 (de) | 1999-06-30 | 2003-11-15 | Merck & Co Inc | Src-kinase hemmende verbindungen |
| JP2003503351A (ja) | 1999-06-30 | 2003-01-28 | メルク エンド カムパニー インコーポレーテッド | Ｓｒｃキナーゼ阻害化合物 |
| IL147150A0 (en) | 1999-07-16 | 2002-08-14 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
| ES2208364T3 (es) | 1999-07-16 | 2004-06-16 | Warner-Lambert Company Llc | Procedimiento para tratar dolor cronico usando inhibidores de mek. |
| GB9919558D0 (en) | 1999-08-18 | 1999-10-20 | Hoechst Schering Agrevo Gmbh | Fungicidal compounds |
| KR20070053362A (ko) | 1999-11-23 | 2007-05-23 | 메틸진, 인크. | 히스톤 디아세틸라제의 억제제 |
| US6770666B2 (en) | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
| TR200103147T1 (tr) | 1999-12-27 | 2002-06-21 | Japan Tobacco Inc. | Kaynaşık halkalı bileşikler ve bunların ilaç olarak kullanımı. |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| AU2002227269A1 (en) | 2000-11-07 | 2002-06-03 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| WO2008108741A1 (en) | 2007-03-07 | 2008-09-12 | S*Bio Pte Ltd | Combination of benzimidazole anti-cancer agent and a second anti-cancer agent |
| CA2450555A1 (en) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| US20060058553A1 (en) | 2002-02-07 | 2006-03-16 | Axys Pharmaceuticals, Inc. | Novel bicyclic hydroxamates as inhibitors of histone deacetylase |
| PL401638A1 (pl) | 2002-03-13 | 2013-05-27 | Array Biopharma Inc. | N3 alkilowane pochodne benzimidazolu jako inhibitory MEK |
| JP2005526076A (ja) | 2002-03-13 | 2005-09-02 | アレイ バイオファーマ、インコーポレイテッド | Ｍｅｋ阻害剤としてのｎ３アルキル化ベンズイミダゾール誘導体 |
| EP1502916A4 (en) | 2002-04-16 | 2006-05-31 | Teijin Ltd | Piperidin derivatives with CCR3-antagonism |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| US7151096B2 (en) | 2003-03-05 | 2006-12-19 | Irm Llc | Cyclic compounds and compositions as protein kinase inhibitors |
| US7169801B2 (en) | 2003-03-17 | 2007-01-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7781595B2 (en) | 2003-09-22 | 2010-08-24 | S*Bio Pte Ltd. | Benzimidazole derivatives: preparation and pharmaceutical applications |
| US20050159470A1 (en) | 2003-12-19 | 2005-07-21 | Syrrx, Inc. | Histone deacetylase inhibitors |
| US20050137234A1 (en) | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
| WO2006101456A1 (en) | 2005-03-21 | 2006-09-28 | S*Bio Pte Ltd | Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors |
| WO2007030080A1 (en) | 2005-09-08 | 2007-03-15 | S*Bio Pte Ltd | Heterocyclic compounds |
| AU2006201177B2 (en) * | 2005-09-08 | 2012-06-14 | Mei Pharma, Inc. | Heterocyclic compounds |
| PL2914254T3 (pl) | 2012-10-30 | 2020-09-07 | Mei Pharma, Inc. | Terapie skojarzone w leczeniu nowotworów chemoodpornych |
-
2017
- 2017-04-28 AR ARP170101104A patent/AR108257A1/es unknown
- 2017-05-01 SG SG11201809471UA patent/SG11201809471UA/en unknown
- 2017-05-01 EA EA201892341A patent/EA201892341A1/ru unknown
- 2017-05-01 CN CN201780041511.XA patent/CN109414425A/zh active Pending
- 2017-05-01 MX MX2018013349A patent/MX382095B/es unknown
- 2017-05-01 ES ES17793075T patent/ES2886495T3/es active Active
- 2017-05-01 BR BR112018072439-4A patent/BR112018072439A2/pt not_active IP Right Cessation
- 2017-05-01 US US16/098,435 patent/US10626092B2/en not_active Expired - Fee Related
- 2017-05-01 KR KR1020187034681A patent/KR20190005904A/ko not_active Abandoned
- 2017-05-01 CA CA3022011A patent/CA3022011A1/en not_active Abandoned
- 2017-05-01 EP EP21178272.7A patent/EP3939966A1/en not_active Withdrawn
- 2017-05-01 EP EP17793075.7A patent/EP3452035B1/en active Active
- 2017-05-01 WO PCT/US2017/030414 patent/WO2017192451A1/en not_active Ceased
- 2017-05-01 AU AU2017261218A patent/AU2017261218A1/en not_active Abandoned
- 2017-05-01 MA MA044880A patent/MA44880A/fr unknown
- 2017-05-01 JP JP2018555958A patent/JP2019514905A/ja active Pending
- 2017-05-02 TW TW106114551A patent/TW201741286A/zh unknown
-
2018
- 2018-10-24 IL IL262578A patent/IL262578A/en unknown
- 2018-10-29 PH PH12018502296A patent/PH12018502296B1/en unknown
- 2018-10-31 CL CL2018003109A patent/CL2018003109A1/es unknown
- 2018-11-29 CO CONC2018/0012941A patent/CO2018012941A2/es unknown
-
2020
- 2020-03-09 US US16/813,230 patent/US20200317621A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20200317621A1 (en) | 2020-10-08 |
| EP3452035A1 (en) | 2019-03-13 |
| TW201741286A (zh) | 2017-12-01 |
| AU2017261218A1 (en) | 2018-11-29 |
| EA201892341A1 (ru) | 2019-05-31 |
| PH12018502296A1 (en) | 2019-07-08 |
| EP3452035A4 (en) | 2019-09-25 |
| MX2018013349A (es) | 2019-02-20 |
| IL262578A (en) | 2018-12-31 |
| BR112018072439A2 (pt) | 2019-02-19 |
| KR20190005904A (ko) | 2019-01-16 |
| EP3939966A1 (en) | 2022-01-19 |
| SG11201809471UA (en) | 2018-11-29 |
| MA44880A (fr) | 2021-03-17 |
| PH12018502296B1 (en) | 2022-04-06 |
| JP2019514905A (ja) | 2019-06-06 |
| US20190152923A1 (en) | 2019-05-23 |
| ES2886495T3 (es) | 2021-12-20 |
| US10626092B2 (en) | 2020-04-21 |
| WO2017192451A1 (en) | 2017-11-09 |
| CO2018012941A2 (es) | 2018-12-28 |
| AR108257A1 (es) | 2018-08-01 |
| CN109414425A (zh) | 2019-03-01 |
| CL2018003109A1 (es) | 2019-04-26 |
| EP3452035B1 (en) | 2021-07-07 |
| CA3022011A1 (en) | 2017-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3448874A4 (en) | COMPOSITIONS FOR TREATING A DISEASE | |
| EP3448987A4 (en) | COMPOSITIONS FOR TREATING A DISEASE | |
| MA49752A (fr) | Procédés de préparation de composés de pyrrolidine | |
| EP3481402A4 (en) | CONNECTIONS, COMPOSITIONS AND METHODS FOR TREATING A DISEASE | |
| EP3675859A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE | |
| EP3484504A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE | |
| MX2018003284A (es) | Compuestos antifungicos y procesos para hacerlos. | |
| PH12016501941A1 (en) | Use of heterocyclic compounds for controlling nematodes | |
| PH12017500920B1 (en) | 4-oxo-3,4-dihydro-1,2,3-benzotriazine as modulators of gpr139 | |
| PH12018502296B1 (en) | Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof | |
| TWI799397B (zh) | 用於治療高血壓之組合物 | |
| WO2016092561A3 (en) | Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof | |
| PH12016501613B1 (en) | Pyrazines modulators of gpr6 | |
| IL259297A (en) | Heterocyclic compounds for the treatment of disease | |
| PL3618826T3 (pl) | Kompozycje do leczenia zakażeń patogenami | |
| MY188420A (en) | Crystalline forms of (s)-afoxolaner | |
| WO2015001541A3 (en) | Pharmaceutical film composition | |
| HUE065955T2 (hu) | Készítmények vulvodynia kezelésére | |
| EP3655379A4 (en) | Methods for preparing bis-tetrahydroisoquinoline-containing compounds | |
| GB201500867D0 (en) | Compound or mixture of compounds for the treatment of neurodegenerative diseases or oxidative stress injuries | |
| NZ735249A (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer’s disease | |
| WO2015170340A3 (en) | Novel polymorphs of sitagliptin hydrochloride, processes for its preparation and pharmaceutical composition thereof | |
| HK40070316B (zh) | 用於治疗疾病的杂环化合物 | |
| SMT202400184T1 (it) | Composizioni per il trattamento di infezioni patogene | |
| HK40015207A (en) | Compositions for the treatment of hypertension |